Secondary diseases and Burkitt’s lymphoma in HIV-infected patients


Cite item

Full Text

Abstract

The authors give the clinical data of 110 human immunodeficiency virus (HIV)-infected patients who stayed in a correctional facility during 2014. Of the examinees, there were almost 50% of the patients with advanced stages (IVA—IVB) with different secondary/opportunistic diseases, among which was Burkitt’s lymphoma, a rather rare malignant disease that developed in obvious immunodeficiency in the absence of antiretroviral therapy.

References

  1. ВИЧ-инфекция и СПИД. Национальное руководство. Под ред. Покровского В.В. Краткое издание. М.: ГЭОТАР-Медиа; 2014.
  2. Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции 2009. М.: Р. Валент; 2010.
  3. Zoufaly A, Stellbrink HJ, der Heiden M. Insufficient virus suppression during HAART is a strong predictor for the development of AIDS-related lymphoma. Abstract 16, 15th CROI 2008, Boston.
  4. Levine AM. AIDS-related lymphoma: clinical aspects. Semin Oncol. 2000;27:442-453.
  5. Hoffmann C, Wolf E, Fatkenheuer G. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003;17:1521-1529.
  6. Lim ST, Karim R, Nathwani BN. AIDS-related Burkitt,s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430-4438.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies